Latest Rhinology Stories

Breathe Again(TM), Europe's best selling hypertonic saline nasal spray, is now available in the United States. Clinically tested in France, Breathe Again (www.breatheagain.us) is 100% natural, combining the benefits of pure seawater and the drying effect of a hypertonic solution. Harvested from Europe's purest tidal seawater off the coast of Saint Malo, France, the superior and unique nasal spray can be used for allergy prevention, nasal congestion, sinus problems and nasal hygiene. With...

Sanofi-Aventis has announced that the FDA has approved Nasacort AQ nasal spray for children aged two to five years old for the treatment of nasal symptoms associated with seasonal and perennial allergic rhinitis. The FDA based its approval on the results of a multicenter, randomized, double-blind, placebo-controlled study demonstrating that Nasacort AQ can be used safely and effectively to treat nasal symptoms of year-round allergies in children between two and five years. This is said to...

CHICAGO, Sept. 24 /PRNewswire/ -- In studies presented this week at the American Academy of Otolaryngology-Head and Neck Surgery Annual Meeting, researchers found that Coblation(R)-assisted procedures eliminated the risk of airway fires, and Coblation(R)-Assisted Sinus Surgery (CASS) procedures lowered the risk of blood loss in nasal polypectomy/endoscopic sinus surgery (ESS). Results of a study, sponsored by ArthroCare and entitled, "Device-Related Risk of Airway Fire in Oropharyngeal...

BRIDGEWATER, N.J., Sept. 23 /PRNewswire-FirstCall/ -- Sanofi-aventis announced today the U.S. Food and Drug Administration (FDA) has approved Nasacort AQ Nasal Spray (triamcinolone acetonide) for children aged 2-5 years old for the treatment of nasal symptoms associated with seasonal and perennial allergic rhinitis. The FDA based its approval on the results of a multicenter, randomized, double-blind, placebo-controlled study demonstrating that Nasacort AQ can be used safely and effectively...

Entellus Medical, a Minnesota-based medical technology company, today announced the launch of its FinESS Sinus Treatment, a less-invasive and effective treatment for chronic rhinosinusitis (CRS), during the American Academy of Otolaryngology Annual Meeting in Chicago September 21-24. Results of the BREATHE I clinical study validating the FinESS treatment were presented to members of the American Rhinologic Society (ARS) during its annual meeting in Chicago on September 20. FinESS Sinus...

MENLO PARK, Calif., Sept. 22 /PRNewswire/ -- Two multicenter studies published this week in Otolaryngology - Head and Neck Surgery confirm Balloon Sinuplasty(TM) technology is safe and effective when used by physicians to treat chronic sinusitis patients. The foundation for those studies was a six-month clinical trial called CLEAR that began in 2005. It included 109 patients who had minimally invasive sinus surgery with the Balloon Sinuplasty(TM) technology. They participated in one-year...

By Prithvijit Mitra Kolkata: Does your doctor prescribe antibiotics every time you have a bout of sinusitis? Beware, you may be headed for deep trouble. Most doctors in the city ignore warnings by the World Health Organization (WHO) and ask patients to pop high power antibiotics even in the case of viral sinusitis, where these pills are useless. Forty-year-old Anjan Das learnt this reality the hard way. He was given antibiotics whenever he had sinusitis. Two years ago, the engineer...

By Anna Wilde Mathews Sinus infections are among the most common and aggravating medical conditions, diagnosed in about 31 million Americans each year. And for most patients, treatment has long included an antibiotic. Now, medical experts are pushing for a less-aggressive approach. About 21 percent of antibiotic prescriptions for adults in the U.S. are for sinusitis, even though studies show the drugs often do little or no good. Short-term sinusitis can be caused by either a bacterial...

DENVER, Aug. 7 /PRNewswire/ -- Quest Product Development, with partner University of Colorado, has been awarded a $1,000,000 Small Business Technology Transfer grant by the National Institutes of Health (NIH) to continue the development of a next-generation endoscope. MicroFlex technology, derived from aerospace engineering, uses shape metal alloys and micro-actuators that allow active control over the shape of the scope for minimally invasive surgery. Surgeons will guide this ultra-slim...

Meda has submitted the registration application to the FDA for azelastine nasal spray in the new formulation with extra strength. The application seeks approval to treat symptoms of seasonal allergic rhinitis and perennial allergic rhinitis. The new formulation is patent pending. Six Phase III studies evaluating efficacy and safety and long term safety have been conducted involving about 1,600 patients treated with azelastine extra strength. The higher strength has been shown to offer...